Clinical trial · Observational
Interest of Reticulocyte Haemoglobin Content (RET-he) in Management of Functional Anemia for Patient With Solid Tumor
Investigating the Value of Reticulocyte Haemoglobin Content (RET-he) in the Management of Functional Martial Deficiency Anaemia in Patients With Solid Tumours
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Determine the value of the initial measurement of the hemoglobin content of reticulocytes (RET-He) for predicting the response to martial treatment for patients with a solid tumor with a functional martial deficiency as defined NCCN2016 (with or without inflammation). The aim is to refine the current definition of functional martial deficiency in order to best adapt the iron prescription in oncology by giving iron only if necessary, i.e. if the RET is low.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Anemia Deficiency | — | UNRESOLVED | — |
| Solid Tumor, Adult | Adult Solid Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Haemoglobin measure | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Haemoglobin measure
- description
- Anaemic adult Patients eligible to iron Treatment supported within the ICO for a solid tumor, untreated or treated by chemotherapy and/or radiotherapy and/or surgery, having benefited of a blood test (NFS, reticulocytes with RET-He , a martial blood test (iron, transferrin and Ferritin), a CRP, vitamins B12 and B9, a creatinine, a haptoglobin, a TSH) before and after iron treatment.
- interventionNames
- Biological: Haemoglobin measure
Primary outcomes (1)
- measure
- Spearman Correlation Coefficient Between RET-He at Baseline and Hemoglobin at 1 Month After Intravenous Iron Treatment
- timeFrame
- 1 month after inclusion
- description
- Spearman correlation between RET-He measured at baseline (initial blood test) and hemoglobin level measured 1 month after intravenous iron treatment.
Secondary outcomes (1)
- measure
- Percentage of Participants With Hemoglobin Increase ≥1 g/dL 1 Month After Intravenous Iron Treatment (With or Without Erythropoiesis-stimulating Agent)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age ≥ 18 years. * Metastatic solid tumor or not. * Anemia by functional martial deficiency (as defined in the NCCN2016 recommendations): o Hb \< 11 g/DL, TSAT \< 20% and ferritinlike between 30 and 800 ng/ml * Initial assessment of anemia carried out at the laboratory of Biopathology of the ICO Exclusion Criteria: * Patient with malignant hemopathy. * Patient with chronic renal failure with an estimation of renal filtration rate according to the formula CKD-EPI \< 60 ml/min/1.73 m². * Patient with vitamin B12 deficiency, folate deficiency, hemolysis and/or hemoglobinopathy. * Patient with active infection. * Patient with bone marrow tumor. Confirmation by a osteo-medullary biopsy (BOM) or a myelogram is not necessary to exclude the patient. * Patient who received ASE within two months prior to the initial blood test. * Patient who received iron (oral or injectable) in the two months preceding the initial blood test. * Patient who received a transfusion of globular pellets in the month preceding the initial blood test.
References
Publications (0)
Data not yet available